Ao Shen

Title: Ao Shen: Innovator in Antiviral and Genetic Research

Introduction

Ao Shen is a prominent inventor based in Guangzhou, China. He has made significant contributions to the fields of antiviral research and genetic engineering. With a total of 2 patents, his work focuses on innovative methods to combat viral infections and manipulate genetic material.

Latest Patents

One of Ao Shen's latest patents is titled "Polypeptide-coupled small molecule compound and antiviral application thereof." This invention provides a polypeptide-coupled small molecule compound that links a specific polypeptide sequence with a small molecule capable of inhibiting the activity of papain-like protease (PLpro) of coronavirus. The compound is designed to inhibit the replication of coronavirus in the host, showcasing advantages such as synergistic inhibition, low cytotoxicity, and favorable solubility.

Another notable patent is the "Targeted DNA demethylation method, fusion protein and application thereof preliminary class." This invention introduces a targeted DNA demethylation method known as Mini-CRISD. It utilizes engineered miniature dCjCas9 to deliver a demethylation effector to specific DNA sequences, achieving targeted demethylation of specific genomic locations.

Career Highlights

Ao Shen has worked with notable institutions, including Guangzhou Medical University and Gmu New Drug Development Co., Ltd. His research has been pivotal in advancing the understanding of antiviral mechanisms and genetic modifications.

Collaborations

Throughout his career, Ao Shen has collaborated with esteemed colleagues such as Xiyong Yu and Hua Tao. Their combined expertise has contributed to the success of various research projects and innovations.

Conclusion

Ao Shen's innovative work in antiviral research and genetic engineering highlights his role as a leading inventor in these fields. His patents reflect a commitment to developing effective solutions for pressing health challenges.